Tetrahydrocannabinol

Tetrahydrocannabinol (CAS 1972-08-3), commonly referenced as Δ9-THC, is the primary psychoactive cannabinoid derived from Cannabis sativa. Marinol is the established pharmaceutical trade name under which synthetic THC has been approved for clinical use.

It functions as the active pharmaceutical ingredient in regulated drug formulations targeting appetite stimulation and nausea suppression. In pharmaceutical manufacturing, Δ9-THC is formulated as the active ingredient in oral capsules.

These capsules are used for chemotherapy-induced nausea and AIDS-related anorexia, where it acts on the endocannabinoid system to produce therapeutic effects. Licensed cannabis producers and API manufacturers source it for inclusion in drug products.

Standardized cannabinoid-based drug products are subject to Schedule I/II regulatory frameworks. Research institutions and clinical trial sponsors procure reference-grade material for pharmacokinetic studies and bioavailability testing.

Analytical method development, forensic, and quality control laboratories also require certified reference standards. These are essential for potency testing and compliance verification of cannabis-derived products in the industry.

Tetrahydrocannabinol is supplied as a reference standard solution, typically in ethanol or methanol at defined concentrations. It is also available as neat oil for pharmaceutical and research applications.

Certified reference material grades meeting USP and ISO 17034 specifications are available for analytical and regulatory use. Supply is strictly controlled under international narcotics conventions for safety.

Procurement requires appropriate DEA, Home Office, or equivalent national authority licensing. This ensures that all distribution of the chemical remains within the legal frameworks of the specific jurisdiction.